Sunitinib dose escalation after disease progression in metastatic renal cell carcinoma.

被引：0
|
作者：
Raphael, Jacques
Thawer, Alia
Bjarnason, Georg A.
机构：
[1] Univ Toronto, Sunnybrook Odette Canc Ctr, Div Med Oncol, Dept Med, Toronto, ON, Canada
[2] Sunnybrook Odette Canc Ctr, Dept Pharm, Toronto, ON, Canada
[3] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.458
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
458
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma
    Raphael, Jacques
    Thawer, Alia
    Bjarnason, Georg A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (01) : 12.e1 - 12.e6
  • [2] Sunitinib Dose Escalation in Metastatic Renal Cell Carcinoma
    Bruchbacher, Andreas
    Nachbargauer, Sebastian
    Fajkovic, Harun
    Schmidinger, Manuela
    KIDNEY CANCER, 2019, 3 (02) : 103 - 110
  • [3] Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma.
    Ornstein, Moshe Chaim
    Elson, Paul
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Wood, Laura S.
    Allman, Kimberly D.
    Martin, Allison
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma
    Mitchell, Nicola
    Fong, Peter C. C.
    Broom, Reuben J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 (03) : E1 - E5
  • [5] Dose escalation of axitinib on disease progression as a strategy in the treatment of metastatic renal cell carcinoma
    Doherty, Gary Joseph
    Lynskey, Deirdre
    Matakidou, Athena
    Fife, Kate
    Eisen, Tim
    ESMO OPEN, 2018, 3 (07)
  • [6] Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma
    Ornstein, Moshe C.
    Wood, Laura
    Elson, Paul
    Allman, Kimberly
    Beach, Jenn
    Martin, Allison
    Gilligan, Timothy
    Garcia, Jorge A.
    Rini, Brian I.
    BJU INTERNATIONAL, 2015, 116 : 18 - 18
  • [7] Dose Escalation and Pharmacokinetics Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
    Schmidinger, Manuela
    Szczylik, Cezary
    Sternberg, Cora N.
    Kania, Marek
    Kelly, Claudia Sue
    Decker, Rodney
    Hamid, Oday
    Faelker, Taron
    Escudier, Bernard
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (05): : 493 - 497
  • [8] Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
    Maraz, Aniko
    Cserhati, Adrienn
    Uhercsak, Gabriella
    Szilagyi, Eva
    Varga, Zoltan
    Revesz, Janos
    Koszo, Renata
    Varga, Linda
    Kahan, Zsuzsanna
    BMC CANCER, 2018, 18
  • [9] Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
    Anikó Maráz
    Adrienn Cserháti
    Gabriella Uhercsák
    Éva Szilágyi
    Zoltán Varga
    János Révész
    Renáta Kószó
    Linda Varga
    Zsuzsanna Kahán
    BMC Cancer, 18
  • [10] Everolimus in advanced/metastatic renal cell carcinoma in adults after sunitinib progression
    Martin-Vila, A.
    Alvarez-Payero, M.
    Martinez-Lopez de Castro, N.
    Suarez-Santamaria, M.
    Castro-Dominguez, J. M.
    Ascunce-Saldana, M. D. P.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 907 - 907
12345